BACKGROUND: Hospitalists improve efficiency, but little information exists regarding whether they impact quality of care.
INTRODUCTION
Congestive heart failure affects 5 million Americans and costs 30 billion dollars annually 1 , with much of these costs incurred during approximately 1 million yearly hospitalizations. 2 Given the prevalence and costs of congestive heart failure, inpatient quality of care for heart failure has become a focus of a number of organizations (e.g., the Joint Commission, Center for Medicare and Medicaid Services). 3, 4 Despite the growing emphasis, there is still substantial room for improvement in many health-care delivery systems. 5, 6 Previous studies suggest that physicians' practice patterns influence quality, with cardiologists tending to have better performance on acute congestive heart failure process and outcome measures compared to generalists. 7, 8 However, generalist physicians continue to care for the majority of decompensated heart failure patients, and increasingly, the generalists providing this care are hospitalists. 8, 9 Previous authors hypothesized that hospitalists may improve quality because of increased experience with acute medical illnesses, increased availability to address changes in clinical status, or because hospitalists are more involved in hospital quality initiatives. 10, 11 Most studies of hospitalist systems have suggested cost and length of stay reductions with no adverse effects on readmissions or patient satisfaction. 12, 13 Few studies have examined care quality, with only one reporting hospitalists' effect on quality of heart failure care. 13 To explore the effect of hospitalists on care of patients with acute congestive heart failure, we examined data from a cohort of patients within the Multicenter Hospitalist (MCH) study. Our primary hypothesis was that hospitalist physicians would have higher completion rates of acute congestive heart failure quality of care processes compared to non-hospitalists. Additionally, we hypothesized that hospitalists would have decreased lengths of stay, costs, and 30-day combined readmissions and mortality.
METHODS
Sites. The Multicenter Hospitalist (MCH) study was a prospective multicenter observational study of the effect of hospitalist care on patients admitted to general medical services. Patient enrollment occurred between 1 July 2001 and 30 June 2003 at six geographically diverse academic medical centers: University of Chicago, University of Wisconsin, University of California at San Francisco, Brigham and Women's Hospital, University of Iowa, and University of New Mexico. These sites were selected because hospitalist or non-hospitalist physicians (none of whom were cardiologists) cared for the majority of patients admitted to the general medical service at each center, and because they primarily used a system where patients were admitted to attending physicians essentially at random, according to day of the week. The MCH study was reviewed and approved by each centers' institutional review board.
MCH Study Patients.
Patients were eligible if they were admitted by a hospitalist or non-hospitalist physician, were 18 years of age or older, and were able to give consent themselves or had an appropriate proxy. Patients were admitted to a hospitalist or non-hospitalist based on a pre-determined call schedule. The MCH study excluded patients admitted specifically under the care of their primary care physician or specialty physician (e.g., oncologist), and those with Mini-Mental Status Examination score of 17 out of 22 or lower. 15 Informed consent for chart abstraction and interviews was obtained from eligible patients.
Congestive Heart Failure Patients. Within the MCH-eligible patients, we retrospectively identified those with heart failure using International Classification of Diseases (ICD-9) diagnosis codes (Appendix 1) assigned at discharge. Patients identified by ICD-9 codes were excluded if they had severe chronic obstructive pulmonary disease (defined as being oxygen dependent, on oral steroids, or having a forced expiratory volume in 1 s of <0.8 l/s), sepsis, fluid overload secondary to renal failure, constrictive pericardial disease, a cardiac surgery planned within 24 h of admission, or having had a thoracotomy in the preceding 2 weeks 16 .
Data Collection. Data were obtained from administrative sources, patient interviews, chart abstractions, and the National Death Index (NDI) database. Administrative data were used to obtain dates of admission and discharge, diagnosis codes (used to identify patients with heart failure, as above), insurance type, age, race, and gender. Intake interviews collected socioeconomic information not available in administrative data (such as education), functional status, and comorbidity data. One month follow-up telephone interviews assessed whether or not the patient had any follow-up appointments or rehospitalizations. 17 A NDI search was used to ascertain 30-day mortality from the date of hospital discharge. 18 Congestive heart failure process and risk adjustment data (such as use of angiotensin-converting enzyme inhibitors at discharge or ejection fraction) were collected by chart abstraction. Principal investigators at each site were responsible for training and overseeing interviews and chart abstraction activities, with central oversight of data quality provided by the coordinating center.
Identification of Hospitalist and Non-Hospitalist Physicians. Hospitalists were defined as physicians whose primary focus is the care of general medical hospitalized patients, and whose activities include patient care, teaching, or research. 19 Nonhospitalist physicians were most often outpatient general internal medicine faculty or non-cardiology subspecialists, who typically attended 1 month per year. Physicians were classified as hospitalists or non-hospitalists according to designations provided by each site. Physician designation was confirmed by site coordinators and linked to the attending physician at discharge using administrative data files.
Quality Measures. We selected three process measures available in guidelines present at the time of the MCH, many of which are elements of current public-reporting initiatives. 3, 4, 20 These processes included: (1) measurement of left ventricular ejection fraction (LVEF) anytime before or during hospital admission documented either by formal imaging study report, or within admission documentation, (2) prescription of an angiotensinconverting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) at discharge for patients with left ventricular ejection fraction lower than 40%, highest creatinine <3.0 and highest potassium <5.5 in the 48 h prior to discharge, and (3) prescription of beta-blocker in patients with LVEF <40%. Patients were excluded from the two discharge medication measures if there was a documented allergy or adverse reactions. In addition, patients who expired, left against medical advice, or were discharged to hospice were also excluded. We also examined two care processes highlighting coordination of care. First we assessed whether or not patients reported during the 30-day interview a physician visit within a month of discharge, a recommended element of the longitudinal care of heart failure patients. 21 We limited the analysis to physician visits identified by patients as having been scheduled upon discharge. Next, we assessed whether formal inpatient cardiac consultation was obtained, based on literature suggesting improved outcomes with cardiology specialist consultation. 22, 23 Finally, as more stringent measures of quality, we determined the percentage of eligible patients who received all three care processes (LVEF assessment, ACE-I use, and beta-blocker use) and those who received all five measures (the first three plus care coordination measures).
Cardiac Test Utilization. Because guidelines recommend evaluation for cardiac ischemia in selected heart failure patients, 21 we examined use of exercise stress testing (with or without scintigraphy or echocardiography) as well as the use of pharmacologic stress testing (with scintigraphy or echocardiography). In addition, we examined whether or not coronary artery catheterization, with or without percutaneous coronary interventions, was performed.
Cost, Length of Stay, and 30-Day Combined Readmissions and Mortality. Length of stay and cost data were obtained from administrative cost-accounting systems maintained at each site. Readmission within 30 days was defined using readmissions identified in administrative records combined with data collected at time of 30-day follow-up phone call. To guard against recall bias, self-report data were only included for nonsite admissions. 24 Additionally, patients who died within 30 days, or were discharged to hospice, were excluded from the readmission measure. The 30-day post-discharge mortality measure included all deaths identified by the NDI at discharge and up to 30-days, excluding patients discharged to hospice. For purposes of increasing statistical power, we combined both 30-day measures into a single outcome measure.
Statistical Analysis. We first compared patient characteristics using chi-square tests for categorical variables and t-or MannWhitney rank sum tests for continuous variables. A p-value of ≤0.05 was considered statistically significant. Next, we performed multivariable analyses to determine the independent association between hospitalist care and the odds of the patient receiving any process or outcome measures, after adjusting for confounding variables and accounting for clustering at the physician level in generalized estimating equation (GEE) regression models. Cost and length of stay regression models were also fitted using GEE, but the models were built on gamma distributions with log-link functions.
We tested socio-demographic, co-morbidities, and physiologic variables for inclusion in each model (see Appendix 2) . To minimize any potential bias or loss of power that might result from limiting the analysis to patients with complete data, we used the multivariate imputation by chained equations method of multiple imputation, as implemented in STATA, to create ten imputed datasets. 25 Imputation of missing values was restricted to confounding variables. Standard methods were then used to combine results over the ten imputed datasets and to compute summary standard errors, confidence intervals, and p-values taking account of the additional uncertainty due to imputation. We also performed a complete-case analysis as a check on the sensitivity of our results to the missing data.
Covariates were considered for inclusion in multivariable models if they were associated with the primary predictor or outcome of interest at a statistical significance of p≤0.10 in unadjusted analysis. Backwards deletion was then used to select final adjusted models, retaining variables reaching statistical significance at p≤0.05. To further guard against confounding, we included site of care, the strongest correlate of the primary predictor, as well as cardiac consultation (when not treated as an outcome itself) in models with a minimum of 50 events. All analyses were performed using STATA 9.0 (StataCorp, College Station, TX).
RESULTS
Patient Characteristics. A total of 31,000 patients were screened for entry into MCH; 896 (2.9% overall) were admitted to a hospitalist or non-hospitalist and met ICD-9 criteria for congestive heart failure. Informed consent was obtained from 567 of heart failure patients of whom we excluded 147 patients because of clinical criteria and 48 patients because their records were unavailable or incomplete, yielding a final cohort of 372 (Fig. 1) .
Hospitalists cared for 120 (32%) patients and non-hospitalists for 252 (68%). Hospitalist and non-hospitalist physicians' patients were similar (Table 1) , although the proportions of heart failure patients in our study varied according to site.
Quality of Care. Physicians assessed LVEF prior to discharge for 320 (86%) of 372 patients. Among these, 279 (88%) had LVEF assessed between hospital discharge and a year prior to admission. In both unadjusted and adjusted analyses, patients treated by hospitalist and non-hospitalists were equally likely to have LVEF measurement prior to hospital discharge. Results were unchanged after excluding LVEF assessment more than 1 year from admission. Unadjusted and adjusted rates of ACE-I/ARB or beta-blocker prescription at discharge were similar between groups (Table 2) .
Patients cared for by hospitalists had almost two-fold higher adjusted odds of reporting scheduled follow-up within 30 days of hospital discharge and statistically similar odds for cardiology consultation. Adjustment for individual study site accounted for the largest proportion of the change between unadjusted and adjusted analyses for each process measure. There were no adjusted differences in adherence to more stringent composite measures of quality (three of three or five of five measures).
Cardiac Test Utilization. Use of non-invasive tests for ischemia was similar between groups. There were higher unadjusted odds of cardiac catheterization in unadjusted analysis; Figure 1 . Eligible subjects for multicenter hospitalist study-congestive heart failure cohort.
however, this difference was no longer statistically significant after multivariable adjustment (Table 3) .
Length of Stay, Costs, and 30-Day Combined Readmissions and Mortality. There were no statistically significant differences in unadjusted or adjusted length of stay, costs, or combined 30-day readmissions and mortality rates between physician groups (Table 4) .
Sensitivity Analyses. Likelihood of receiving an ACE-inhibitor or ARB was not modified by inclusion of interactions between the physician specialty and patients' creatinine or blood pressure.
Similarly, the interaction between physician specialty and pulse or blood pressure was not significantly associated with receipt of beta-blockers. We also tested for a potential relationship between 30-day follow-up rates and use of procedures (e.g., cardiac catheterization), receiving a new medication, or worse physiologic measures (e.g., lower blood pressure) at discharge, and continued to note higher odds for follow-up in the hospitalist patient group. Finally, results for our complete case sensitivity analysis were essentially unchanged, with one exception: the adjusted odds for patient-reported scheduled 1-month follow-up were no longer statistically significant (OR=1.62, 95% CI 0.98-2.68) in the complete case analysis, with a reduced sample of 228 patients. 
DISCUSSION
Results from our study suggest that across a broad set of quality measures, the performance of hospitalist and nonhospitalist physicians was equivalent among patients with acute congestive heart failure. While quality of care for patients in our study was similar to studies published during the period of the MCH, 5, 6 our data suggest a substantial opportunity for improvement. However, even if care processes in the hospital were not different, hospitalists' patients actually had follow-up more frequently, suggesting that the academic hospitalist model may have a more positive impact on longitudinal care than traditional academic inpatient models. Our results stand in contrast to a community-based study suggesting improved heart failure processes and decreased length of stay in hospitalist systems; 13 this difference is perhaps because of the effect of residents in our study. For example, housestaff play an important patient care role in each of the study's academic centers. Common cultural and clinical practices among housestaff may influence quality performance more than practices of supervising physicians. Alternatively, the hospital systems in our study were likely quite different during the MCH than they were during the time when initial studies of hospitalist programs were published, 12, 17, 26 with more experienced non-hospitalists, more inexperienced hospitalists, growing use of multidisciplinary rounds, standardization of orders, and better case coordination all being potential influences.
Concern about handoff problems and loss of continuity are key criticisms of hospitalist systems. 27 However, we were reassured that patients cared for by hospitalists reported higher rates of follow-up after discharge. While our analyses cannot discern whether follow-up resulted in better outcomes, follow-up is a recommended step to improving decompensated heart failure care and reducing the likelihood of readmission. 20, 21 However, our data cannot discern other more subtle measures of discharge coordination, such as whether the patient understood plans for post-discharge care; without adequate communication, notations of follow-up may not be sufficient to avoid readmission or other adverse outcomes. 27 In contrast to previous studies suggesting no effect of hospitalist systems on rates of specialty consultation, 26, 28 we noted some evidence, though not conclusive, that MCH hospitalists consulted cardiologists more often and more frequently ordered invasive tests. Increases in referrals for congestive heart failure may be because hospitalists were less comfortable caring for heart failure patients or because they were more attentive to reasons why cardiologist care would be needed (e.g., evaluation for revascularization), or recognition that cardiologists may improve quality of care and potentially outcomes as well, 22, 23 particularly in patients with active cardiac ischemia. This latter mechanism is suggested by a trend towards more frequent invasive tests in hospitalists' patients. However, the number of cardiac catheterizations is small, and the appropriateness of testing for cardiac ischemia cannot be ascertained with our data. Our study has several limitations. First, the MCH took place in six academic medical centers, and our findings may not be applicable to hospitalists in community settings. Second, due to a small sample size, our study has limited statistical power to observe small differences in less common outcomes (e.g., cardiac procedures); this is reflected in relatively wide confidence intervals for hospitalist effects on many study outcomes. In addition, without complete ejection fraction information or a full range of laboratory data (such as B-type natriuretic peptide), we may not have fully adjusted for acute severity of illness. However, our cohort was very balanced in most other observable characteristics, making the threat of potential bias very small. Finally, beta-blocker prescription at discharge was not formally recommended in guidelines for inpatient heart failure care at the time of the MCH, potentially weakening the association between this measure of performance and overall quality of care. Despite this, guidelines are known to lag behind clinical evidence, and at the time of the study, evidence for pre-discharge beta-blockers was mounting. 29, 30 In this first multicenter study comparing hospitalists and non-hospitalists in the care of acute congestive heart failure, we did not observe a strong effect of hospitalists on key quality measures, but hospitalists more frequently arranged for follow-up care. Whether our observations would change in an era when acute congestive heart failure measures are publicly reported and whether specific types of physicians respond differently to these newer pressures are worthy subjects for future study. ICD-9-CM description 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified, with heart failure 404.01 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified 404.03 Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease 404.11 Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified (continued on next page) ICD-9 code ICD-9-CM description 404.13 Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease 404.91 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified* 404.93 Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease 428.0 Congestive heart failure, unspecified CHF NOS 428.1 Left heart failure 428.20 Unspecified systolic heart failure 428.21 Acute systolic heart 428.22 Chronic systolic heart failure 428.23 Acute on chronic systolic heart failure 428.30 Unspecified diastolic heart failure 428.31 Acute diastolic heart failure AC 428.32 Chronic diastolic heart failure 428.33 Acute on chronic diastolic heart failure 428.40 Unspecified combined systolic and diastolic heart failure 428.41 Acute combined systolic and diastolic heart failure 428.42 Chronic combined systolic and diastolic heart failure 428.43 Acute on chronic combined systolic and diastolic heart failure 428.9 Heart failure, unspecified
